First VAR2 patent issued

It is with great pleasure that VAR2 Pharmaceuticals can announce that our first patent has been issued by the Australian Government (IP Australia). Key claims on the use of recombinant VAR2CSA for targeting, treating and diagnosing cancer was accepted and issued.

Continue reading

Therapeutic access to cisplatin-resistant bladder cancer using VAR2-Drug Conjugates

Cisplatin is worldwide standard-of-care chemotherapy in muscle-invasive bladder cancer (MIBC). However, many patients develop resistance to cisplatin with no second-line treatment options currently available. A new study published on April 10, 2017 in European Urology demonstrates VAR2-mediated drug......
Continue reading

PEGS conference in Boston May 1-5

VAR2Pharmaceuticals will be present at PEGS conference in Boston May 1-5. To arrange a meeting please contact salanti@var2pharmaceuticals.com

Continue reading

The role of oncofetal CSA is published in a major article

The role of oncofetal CSA is published in a major article in ”Molecular Cancer Research” by the founders of VAR2Pharmaceuticals. The publication was choosen as the front cover of the monthly peer reviewed journal and describes that onco-fetal CSA plays a key role in metastasis formation and that tre......
Continue reading

VAR2Pharmaceuticals announces

VAR2Pharmaceuticals announces the finalization of the second investment round of 3.3M Euros. ”We are very pleased to have secured further funding for our exciting portfolie of pre-clinical development programs” says CEO Ali Salanti.

Continue reading